CMMB

Chemomab Therapeutics Ltd. [CMMB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CMMB Stock Summary

Top 10 Correlated ETFs

CMMB


Top 10 Correlated Stocks

CMMB


In the News

11:20 29 May 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab Therapeutics First Quarter 2023 Earnings Call and Corporate Update.

07:00 29 May 2023 CMMB

Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.

11:43 29 May 2023 CMMB

Chemomab (CMMB) Stock Gains 30% on FDA Clearance

There's potentially positive news for the medical community as well as investors of Chemomab (NASDAQ: CMMB ) today. CMMB stock is moving higher because Chemomab has good news on the regulatory front, plus the company expects to move forward with important clinical research.

08:25 29 May 2023 CMMB

Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment

Shares of Chemomab Therapeutics Ltd. CMMB, -0.51% shot up 46.9% in premarket trading Tuesday, after the Israel-based biotechnology company said the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application to evaluate its systemic sclerosis (SSc) treatment, CM-101.

12:00 29 May 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Chief Financial Officer, Executive Vice President and Chief Operating Officer Adi Mor - Co-Founder and Chief Scientific Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab's Third Quarter 2022 Earnings Conference Call.

07:00 29 May 2023 CMMB

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.

02:40 29 May 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Operator Greetings Welcome to Chemomab Therapeutics 2022 Second Quarter Earnings Call.

07:00 29 May 2023 CMMB

Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.

07:00 29 May 2023 CMMB

Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C.

05:43 29 May 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q1 2022 Results - Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & CEO David Weiner - Interim CMO Don Marvin - CFO, COO & EVP Adi Mor - Co-Founder & Chief Scientific Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Nathan Weinstein - Aegis Capital Operator Greetings and welcome to the Chemomab First Quarter 2022 Earnings Call.

CMMB Financial details

Company Rating
Neutral
Market Cap
17.9M
Income
-31.53M
Revenue
0
Book val./share
2.53
Cash/share
2.96
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
10 Aug 2023
P/E
-0.57
Forward P/E
-
PEG
-0.04
P/S
-
P/B
0.64
P/C
0.55
P/FCF
-0.75
Quick Ratio
4.82
Current Ratio
4.83
Debt / Equity
0.25
LT Debt / Equity
0
-
-
EPS (TTM)
-2.78
EPS next Y
-
EPS next Q
-
EPS this Y
100.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
9.72%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-33.33%
Inst Own
1.27%
Inst Trans
-0.18%
ROA
-90%
ROE
-79%
ROC
-1.15%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
11.05M
Shs Float
10.36M
-
-
-
-
Target Price
-
52W Range
1.375-5.35
52W High
-67.6%
52W Low
+62%
RSI
50
Rel Volume
0.28
Avg Volume
39.45K
Volume
11K
Perf Week
-11.96%
Perf Month
-0.61%
Perf Quarter
-20.98%
Perf Half Y
-19%
-
-
-
-
Beta
-0.229218
-
-
Volatility
0.07%, 0.11%
Prev Close
-1.22%
Price
1.62
Change
-3.57%

CMMB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2020-12-312021-12-31 2022-12-31
Revenue per share
000
Net income per share
-0.54-1.21-2.43
Operating cash flow per share
-0.48-1.19-1.79
Free cash flow per share
-0.48-1.22-1.8
Cash per share
1.065.93.51
Book value per share
0.985.933.18
Tangible book value per share
0.985.933.18
Share holders equity per share
0.985.933.18
Interest debt per share
0.040.040.05
Market cap
304.56M71.58M36.41M
Enterprise value
293.31M56.73M23.11M
P/E ratio
-51.36-5.69-1.32
Price to sales ratio
000
POCF ratio
-58.1-5.78-1.79
PFCF ratio
-57.68-5.67-1.78
P/B Ratio
28.191.161.01
PTB ratio
28.191.161.01
EV to sales
000
Enterprise value over EBITDA
-49.31-4.6-0.81
EV to operating cash flow
-55.95-4.58-1.13
EV to free cash flow
-55.55-4.5-1.13
Earnings yield
-0.02-0.18-0.76
Free cash flow yield
-0.02-0.18-0.56
Debt to equity
0.150.050.19
Debt to assets
0.130.040.16
Net debt to EBITDA
1.891.20.47
Current ratio
923.666.18
Interest coverage
0-111.41-80.83
Income quality
0.880.990.74
Dividend Yield
000
Payout ratio
000
Sales general and administrative to revenue
000
Research and developement to revenue
000
Intangibles to total assets
000
Capex to operating cash flow
0.010.020
Capex to revenue
000
Capex to depreciation
-1.58-7.03-1.17
Stock based compensation to revenue
000
Graham number
3.4512.7213.19
ROIC
0.54-0.38-1.95
Return on tangible assets
-0.48-0.2-0.64
Graham Net
0.925.632.93
Working capital
10.52M60.04M34.99M
Tangible asset value
10.8M61.47M36.22M
Net current asset value
10.17M59.8M34.9M
Invested capital
0.040.010.01
Average receivables
0126.5K319K
Average payables
0714.5K1.51M
Average inventory
000
Days sales outstanding
000
Days payables outstanding
000
Days of inventory on hand
000
Receivables turnover
000
Payables turnover
000
Inventory turnover
000
ROE
-0.55-0.2-0.76
Capex per share
0-0.02-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
Revenue per share
00000
Net income per share
-0.47-0.54-0.73-0.72-0.79
Operating cash flow per share
-0.33-0.5-0.46-0.5-0.65
Free cash flow per share
-0.33-0.5-0.46-0.5-0.65
Cash per share
5.034.534.063.492.96
Book value per share
5.024.543.93.172.53
Tangible book value per share
5.024.543.93.172.53
Share holders equity per share
5.024.543.93.172.53
Interest debt per share
0.05-0.020.040.05-1.59
Market cap
54.74M42.21M28.48M36.6M17.57M
Enterprise value
41.23M32.61M17.99M23.3M-3.02M
P/E ratio
-2.57-1.7-0.86-1.11-0.5
Price to sales ratio
00000
POCF ratio
-14.75-7.4-5.42-6.42-2.44
PFCF ratio
-14.7-7.39-5.38-6.42-2.44
P/B Ratio
0.960.810.641.010.63
PTB ratio
0.960.810.641.010.63
EV to sales
00000
Enterprise value over EBITDA
-7.77-5.23-2.17-2.70.33
EV to operating cash flow
-11.11-5.72-3.42-4.090.42
EV to free cash flow
-11.07-5.71-3.4-4.080.42
Earnings yield
-0.1-0.15-0.29-0.23-0.5
Free cash flow yield
-0.07-0.14-0.19-0.16-0.41
Debt to equity
0.060.090.130.190.25
Debt to assets
0.060.080.110.160.2
Net debt to EBITDA
2.551.541.261.542.28
Current ratio
16.8712.488.96.184.83
Interest coverage
-24.6313.03-35.09-22.740.51
Income quality
0.730.920.650.690.82
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
000.0100
Capex to revenue
00000
Capex to depreciation
-1.08-0.79-2.47-0.07-0.06
Stock based compensation to revenue
00000
Graham number
7.267.457.997.186.71
ROIC
-0.17-0.16-0.31-0.61.04
Return on tangible assets
-0.09-0.11-0.17-0.19-0.25
Graham Net
4.834.343.722.922.39
Working capital
55.82M50.44M43.25M34.99M26.78M
Tangible asset value
57.24M51.84M44.62M36.22M27.95M
Net current asset value
55.62M50.29M43.13M34.9M26.72M
Invested capital
0.010.010.010.010.01
Average receivables
1.06M2.52M2.68M1.36M727K
Average payables
1.41M1.46M1.34M1.47M1.95M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
020.6213.49022.05
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
04.366.6704.08
Inventory turnover
00000
ROE
-0.09-0.12-0.19-0.23-0.31
Capex per share
00000

CMMB Frequently Asked Questions

What is Chemomab Therapeutics Ltd. stock symbol ?

Chemomab Therapeutics Ltd. is a IL stock and trading under the symbol CMMB

What is Chemomab Therapeutics Ltd. stock quote today ?

Chemomab Therapeutics Ltd. stock price is $1.62 today.

Is Chemomab Therapeutics Ltd. stock public?

Yes, Chemomab Therapeutics Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap